The Technical Analyst
Alaunos Therapeutics, [TCRT]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Alaunos Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
8.33% $1.300
America/New_York / 24 apr 2024 @ 12:01
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 20.82 mill |
| EPS: | -33.00 |
| P/E: | -0.0400 |
| Earnings Date: | May 07, 2024 |
| SharesOutstanding: | 16.01 mill |
| Avg Daily Volume: | 0.0988 mill |
| RATING 2024-04-23 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.0400 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.01x |
| Company: PE -0.0400 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.374 (-71.23%) $-0.926 |
| Date: 2024-04-24 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.070 - 1.450 ( +/- 15.08%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-22 | Groenewald Ferdinand | Buy | 0 | |
| 2024-01-20 | Hogue Dale Curtis Jr. | Buy | 600 000 | Employee Stock Option (right to buy) |
| 2023-12-29 | Hogue Dale Curtis Jr. | Buy | 150 000 | Employee Stock Option (right to buy) |
| 2023-12-29 | Hogue Dale Curtis Jr. | Buy | 41 667 | Employee Stock Option (right to buy) |
| 2023-12-29 | Hogue Dale Curtis Jr. | Buy | 0 |
| INSIDER POWER |
|---|
| 96.80 |
| Last 87 transactions |
| Buy: 16 191 500 | Sell: 2 243 866 |
Forecast:
13:40 - $1.225
Live Trading Signals (every 1 min)
Forecast
1: 12:10 - $1.276
Forecast 2: 13:00 - $1.232
Forecast 3: 13:40 - $1.225
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.300 (8.33% ) |
| Volume | 0.0086 mill |
| Avg. Vol. | 0.0988 mill |
| % of Avg. Vol | 8.72 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TCRT
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:32 | sell | $2.37 | N/A | Active |
|---|
TCRT
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Latest Press Releases
2023-11-14 07:30:00 - Press Release
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data And Continued Exploration Of Strategic Alternatives
Houston, nov. 14, 2023 (globe newswire) -- alaunos therapeutics, inc. (“alaunos” or the “company”) (nasdaq: tcrt), today announced financial results for the third quarter ended september 30, 2023. as previously announced, the company is exploring strategic alternatives with cantor fitzgerald & co. as its strategic advisor. alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.
2023-08-14 16:05:00 - Press Release
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data And Exploration Of Strategic Alternatives
Houston, aug. 14, 2023 (globe newswire) -- alaunos therapeutics, inc. (“alaunos” or the “company”) (nasdaq: tcrt), today announced financial results for the second quarter ended june 30, 2023. the company also announced a strategic reprioritization to focus on its huntr ® tcr discovery platform, wind down its tcr-t phase 1/2 library trial and explore broad strategic alternatives for the company. alaunos is implementing a cost-savings plan that includes a reduction in workforce by approximately 60%.
2023-05-03 08:30:00 - Press Release
Alaunos Therapeutics To Report First Quarter 2023 Financial Results On May 10, 2023
Houston, may 03, 2023 (globe newswire) -- alaunos therapeutics, inc. (“alaunos” or the “company”) (nasdaq: tcrt), a leading t-cell receptor (tcr) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended march 31, 2023, on wednesday, may 10, 2023, before the open of u.s. markets. following the announcement, the company will host a conference call and webcast at 9:00 a.m. et to review the financial results and provide a corporate update.
2023-03-29 17:30:00 - Press Release
Alaunos Therapeutics To Participate In Upcoming Investor Conferences In April
Houston, march 29, 2023 (globe newswire) -- alaunos therapeutics, inc. (“alaunos” or the “company”) (nasdaq: tcrt), a leading t-cell receptor (tcr) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
2023-02-28 16:01:00 - Press Release
Alaunos Therapeutics To Report Fourth Quarter And Full Year 2022 Financial Results On March 7, 2023
Houston, feb. 28, 2023 (globe newswire) -- alaunos therapeutics, inc. (“alaunos” or the “company”) (nasdaq: tcrt), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended december 31, 2022, on tuesday, march 7, 2023, before the open of u.s. markets. following the announcement, the company will host a conference call and webcast at 8:30 a.m. et to review the financial results and provide a corporate update.
Latest News
2023-08-16 11:44:17 - Zacks Investment Research
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
2023-05-03 08:30:00 - GlobeNewsWire
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update.
2023-03-29 17:30:00 - GlobeNewsWire
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
2023-02-28 16:01:00 - GlobeNewsWire
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update.
2023-01-24 11:18:12 - Zacks Investment Research
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
2023-01-18 10:33:52 - Zacks Investment Research
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
2022-11-30 11:17:53 - Zacks Investment Research
After Plunging 42% in 4 Weeks, Here's Why the Trend Might Reverse for Ziopharm (TCRT)
Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
2022-11-21 14:13:04 - Seeking Alpha
Alaunos Therapeutics Still Waiting For Home Run
First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete response rates.
2022-11-18 09:10:15 - Zacks Investment Research
New Strong Buy Stocks for November 18th
VIRC, TCRT, AINC, CWEN and WHF have been added to the Zacks Rank #1 (Strong Buy) List on November 18, 2022.
2022-11-14 14:10:05 - Seeking Alpha
Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript
Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive Officer Abhi Srivastava - Vice President, Technical Operations Drew Deniger - Vice President, Research and Development Mike Wong - Vice President, Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald James Shin - Wells Fargo Yale Jen - Laidlaw Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Alaunos Therapeutics Third Quarter 2022 Financial Results Conference Call.